The efforts of Israeli scientific research have led to the invention of medicine that completely cures the cancer of any type and it will be available from 2020. Israeli scientific research also invented a solution for insulin taking diabetic patients. Also, some other Israeli research group has invented micro pancreas for diabetic patients.
These innovations will become beneficial to people around the world except Iraq, Algeria, Bangladesh, Brunei, Iran, Kuwait, and Pakistan, etc. due to their anti-semitic and anti-Israel mindset. Some Asian countries including India and Nepal can get benefit from these innovations and in the future can be a huge source of export of these medicines in other Asian counties.
“We believe we’ll offer in a year’s time a complete cure for cancer”
— Dan Aridor, Chairman of the board of accelerated evolution biotechnologies Ltd. (AEBi).
AEBi develops the SoAP (simple object access protocol) platform which accesses functional leads over difficult targets. Further Dan Aridor claimed that “Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market and our solution will be both generic and personal”.
According to reports by an international agency for research on cancer, every year 18.1 million new cancer cases diagnosed worldwide and every sixth death in the world is due to cancer making it the second most leading cause of death.
I think it is very fantastic news to combat such a dreadful disease.
Dan Aridor and CEO Dr. Ilan Morad, say their treatment, which they call MuTaTo (multi-target toxin) essentially acts as cancer antibiotic – a disruptive technology of the highest order. Their anti-cancer drug is based on SoAP technology which involves the introduction of foreign DNA coding for a protein, such as an antibody, into a bacteriophage (a virus that infects bacteria). That foreign protein is then displayed on the surface of the phage. Researchers can use these protein-displaying phages to screen for interactions with other proteins, DNA sequences, and small molecules.
AEBi is doing similar to the peptides (compound of two or more amino acids joined by a peptide bond). Use of peptide is advantageous over using antibodies as peptides are smaller, cheaper and easier to produce and regulate.
The first question raised in their mind while discovering novel peptides for specific cancers that why other cancer-killing drugs and treatments eventually fail. After analyzing the problem, they tried to sort out the problem and finally, they found a way.
MuTaTo is using a combination of several cancer-targeting peptides for each cancer cell at the same time along with strong peptide toxin that specifically kills the cancer cells.
Strategies followed by MuTaTo
- Most anti-cancer drugs attack a specific target that alters the physiological pathway. Mutation in any of the specific target or physiological pathway renders drugs ineffective.
MuTaTo is a combination of several cancer-targeting peptides for each cancer cell along with strong peptide toxin that would kill cancer cells specifically and would not be affected by mutations because MuTaTo is attacking at least three targets and so with an increasing number of targets, probability of having multiple mutations decreased dramatically.
Instead of attacking single receptor, MuTaTo attack three receptors at a time and cancer cannot mutate three receptors at the same time.
- Cancer cells activate detoxification mechanism under the stress of anti-cancer drugs, resulted in pumping out of drug from cell and modification that make those drugs non-functional.
MuTaTo operates on the principle that detoxification takes time and strong toxin along with three receptor/target attacking drug has a higher probability of killing cancer cells even before detoxification starts.
- Cancer cells can be of two types i.e. fast-growing and slow-growing cancer stem cells. Most of the anti-cancer drugs target fast-growing cancer cells and thus slow-growing cancer stem cells can remain in the system and escape these treatments. When the treatment is over, recurrence of cancer occurs due to these cancer stem cells. This time cancer stem cells resist the same drug as these new cancer cells over-express new surface receptors.
MuTaTo multiple target attack kills both fast-growing as well as slow-growing cancer stem cells, as most of the over-expressed proteins that are present in fast-growing cancer cells, also present/ over-expressed on cancer stem cells.
- Some cancer cells don’t allow access to large molecules inside them. Peptide parts of MuTaTo are very-small (12 amino acids long) and do not possess a rigid structure. So, it can easily leach into the places where other large particles cannot reach. Also, MuTaTo peptide is non-immunogenic and thus enable repeated administration of the drug.
- MuTaTo discovery also reduces the sickening side-effects of most cancer treatments.
Side-effects associated with most of the cancer treatment drugs are a drug interaction with either wrong or additional targets and drug interaction with the correct target but on a normal cell. MuTaTo is highly specific cancer-targeting peptide that increases the specificity to cancer cells many folds due to avidity effect (strong binding of antigen to antibody). Also, normal cells that have proteins common to cancer cells do not over-express it.
“This makes a huge difference between the two kinds of cells and reduce the associated side-effects dramatically.”
- MuTaTo cancer treatment will eventually be personalized, each patient will provide a piece of biopsy to the lab, which would then analyze it to know which receptors are over-expressed. The patient would then be administered exactly the molecule cocktail needed to cure his/her disease.
“Company is writing patents on specific peptides which will be a large bank of targeting toxin peptides,” said Arcdor.
The company has done so far several in vitro trials along with which first in vivo mice experiment. Which inhibited human cancer cell growth and had no effect on healthy mice cells. AEBi is beginning a round of clinical trials that would be completed within a few years.
Israel innovations to cure diabetes
Diabetes is of two types mainly i.e. type-I diabetes (an autoimmune disorder that destroys pancreatic cells) and type-II diabetes (pancreas doesn’t produce enough insulin). In type-I as well as chronic type-11 diabetes, patients need a daily injection of insulin during their whole life. Israel innovation aimed to treat diabetes by implanting a lab-built micro-pancreata.
Need for creating micro-pancreata instead of injecting healthy pancreatic cells
Transplanted pancreatic cells die quickly within the body due to the body’s immune response, moreover, pancreatic cells don’t work properly in isolation. They need tissues and organ system to function properly.
Micro-pancreata has several interesting features making it an ideal treatment. Innovation such as micro-pancreata is of microscopic dimensions so it can be implanted anywhere in the body and it doesn’t need vascularization rather it works by diffusion. Theoretically, because it’s so small, the micro-pancreas can survive without connecting to the blood systems. But actually, that’s how it monitors our blood glucose and produces the correcting insulin. These micro-pancreases have been a great success in mice, as reported in PLOS ONE.
Micro-pancreata testing technique
Testing the function of these micro-pancreas involved chemically destroying the mice’s insulin-producing cells, then implanting these micro-pancreas into mice. If the mouse lives, the micro-pancreas are working – it’s controlling the animal’s glucose levels. If the mouse dies, it isn’t working.
Professor Eduardo Mitrani said about the testing techniques that “We found we could keep the mice functioning even for three months, the longest period tested”. He further elaborated that without a working pancreas, we (and mice) cannot survive for more than a few days at most. As a control for the experiment, they took mice that had survived all that for a month and removed the micro-pancreas, following which the animals died. To build their micro-pancreas, they used lung tissue instead of using pancreatic cells. Mitrani explained to Haaretz, 95% of pancreases is mainly involved in producing digestive enzymes and not insulin regulation. For another, the lung tissue provides a huge surface area and thus proved most compatible. The father of this hopefully breakthrough technology, and head of the scientific advisory board at Betalin Therapeutics, Prof. Eduardo Mitrani from the Hebrew University of Jerusalem named MIXiii Biomed pharma “the most innovative biopharma company of the year.”
The biggest challenge is; Muslim countries may not welcome this innovation making them the leading victims of Cancer and Diabetes by 2030. Anti-Semitism is very well mixed in the radical Islamic society which not only hurts them but the entire race. This is why today the Muslim world is considered to be the biggest hindrance for innovation. Every year millions come to India for their treatment from many Muslim world countries, especially the transplant surgery. It’s not that they can not have such facilities in their countries, it is because of their orthodoxical radical behavior. Pakistan denied its only Nobel laureate; Dr. Abdus Salam; the only Muslim science laureate, due to his faith as he belongs to the Ahmadiyya Islam which is considered to be a heretic by other Muslim mullahs.
— Muzaffar Ahmad Noori Bajwa (Editor in Chief The Eastern Herald).
Jerusalem based pharmaceutical company has developed an oral insulin capsule that replaces the injecting treatments into oral therapies. These oral capsules are under advanced food and drug administration’s (FDA) clinical trial since 2016 and expected to come in the market from 2020.
Nadav Kidron, CEO, and co-founder of Jerusalem based Oramed pharmaceuticals together with Nobel prize winner Prof. Avram Hershko developed an orally delivered insulin that goes intact into the liver (the organ that regulates the secretion of insulin into the body). Their vision is to treat diabetes by switching to healthy lifestyle habits such as diet, exercise, oral insulin and then eventually injectable insulin.
In November 2015, Oramed signed licensing and investment agreements with Chinese investment and incubation company HTIT for exclusive rights to market company’s insulin capsules in China, Hong Kong, and Macau. The Oramed platform works on the aim of transforming injecting treatments into orally administered pills. Company is currently working on GLP-1 analog that helps in reducing weight and other such related products.
Authored by Aniqa Bajwa; a cancer research scholar at the Panjab University Chandigarh in India.